FANCC and myelodysplastic syndrome: The propensity of our Fancc-/-; Mad2+/- mice to develop early-onset AML provides a valuable tool for the development of evidence-driven therapies to optimize outcomes and decrease therapy-related toxicities in patients with FA who suffer from AML/MDS.